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Abstract
The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with
some patients having a slow progression and others an accelerated clinical and functional
decline. This study aims to clinically characterize the type of progression in IPF and to inves-
tigate the pathological basis that might account for the observed differences in disease
behavior. Clinical and functional data were analyzed in 73 IPF patients, followed long-time
as candidates for lung transplantation. The forced vital capacity (FVC) change/year (< or
10% predicted) was used to define “slow” or “rapid” disease progression. Pathological
abnormalities were quantified in the explanted lung of 41 out of 73 patients undergoing lung
transplantation. At diagnosis, slow progressors (n = 48) showed longer duration of symp-
toms and lower FVC than rapid progressors (n = 25). Eleven slow and 3 rapid progressors
developed an acute exacerbation (AE) during follow-up. Quantitative lung pathology
showed a severe innate and adaptive inflammatory infiltrate in rapid progressors, markedly
increased compared to slow progressors and similar to that observed in patients experienc-
ing AE. The extent of inflammation was correlated with the yearly FVC decline (r = 0.52, p =
0.005). In conclusion an innate and adaptive inflammation appears to be a prominent fea-
ture in the lung of patients with IPF and could contribute to determining of the rate of disease
progression.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrosing intersti-
tial lung disease of unknown cause that carries a dismal prognosis, with a 5-years survival of
approximately 20% [1].
A chronic inflammatory process of the lung has long been considered the main mechanism
underlying IPF [2–6]. However, recently there has been a conceptual transition in IPF patho-
genesis from an inflammatory driven process to a primarily fibrotic one, in which fibrogenesis
results from recurrent microinjury of alveolar epithelial cells followed by aberrant repair
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processes leading to fibrosis [7–9]. Currently the inflammatory process is described as mild
and consisting of a patchy interstitial infiltrate of lymphocytes and plasma cells [10, 11] and is
not considered an important component of IPF pathology or a factor contributing to patho-
genesis of the disease.
The clinical course of IPF is highly heterogeneous, with the majority of patients having a rel-
atively slow progression while the remainder have an accelerated, rapid decay in lung function
and shorter survival [12–14]. In this regard, it has been reported that the global gene expression
in the rapid and slow progression phenotypes differs significantly, with up-regulation of molec-
ular pathways involved in cell motility, fibroblast differentiation and inflammation in the rapid
progressors [13, 14]. Further evidence that IPF does not behave clinically as a single entity
stems from the observed differences in the expression of inflammatory markers and autoanti-
bodies that are associated with different clinical outcomes in patients with IPF [15–23]. Fur-
thermore, patients with IPF can develop an acute exacerbation (AE) of their disease and this
carries a poor prognosis [24]. In spite of this heterogeneous clinical behaviour, these observa-
tions have not been incorporated in the practical approach to the disease, perhaps because
there is insufficient information about the clinical course and corresponding lung pathology in
these patients to justify the segregation of these groups.
In this study we aimed to characterize the type of disease progression, slow or rapid, in a
group of patients with IPF followed for long time before undergoing lung transplantation, and
correlate it with a detailed quantitative study of the pathology of the explanted lung. Indeed we
hypothesized that the different clinical behaviour may be accounted for, at least partially, by
the different lung pathologies. This information might potentially add significantly to the
understanding of pathogenesis and disease behaviour of IPF.
Methods
In this study, we defined the clinical and functional progression in a group of 73 IPF patients
referred for possible lung transplantation to our center in Padova between 2000 and 2014. In
the 41 patients from this group who underwent lung transplantation we performed a quantita-
tive pathological study of the native lung and compared the findings in lung pathology with the
clinical progression.
Clinical analysis
Seventy three patients with IPF referred to our center for possible lung transplantation were
included in the study. IPF was diagnosed according to the ATS/ERS or the ATS/ERS/JRS/
ALAT Guidelines (according to whether they were referred before or after the publication of
the 2011 guidelines) [1, 10, 11]. Information collected retrospectively was integrated with a lon-
gitudinal follow-up to determine the clinical progression of IPF (slow or rapid) from the begin-
ning of symptoms to lung transplantation, death or end of follow-up (up to December 2014).
Medical records were reviewed and data on serial lung function tests, high-resolution com-
puted tomography (HRCT) of the chest, right heart catheterization and/or echocardiography
were collected for all patients. None of the subjects had a clear history of occupational or envi-
ronmental exposure to fibrogenic agents, nor clinical features of hypersensitivity pneumonitis
or connective tissue disease. All patients had negative autoimmune serologic testing including
antinuclear antibodies (ANA), anti-double strand (anti-ds) DNA antibodies, anti-extractable
nuclear antigens (ENA), antineutrophil cytoplasm antibodies (ANCAs) and cyclic citrullinated
peptide (CCP). The study population included 2 brothers with familial IPF.
During follow-up, spirometry was serially performed every 6 to 12 months. The fall in %
predicted FVC per year was used to characterize the disease progression as “rapid” (fall in %
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Abbreviations: AE, Acute Exacerbation; DAD,
Diffuse Alveolar Damage; FEV1, Forced Expiratory
Volume in the 1st second; FVC, Forced Vital
Capacity; IPF, Idiopathic Pulmonary Fibrosis.
predicted FVC 10% per year) and “slow” (fall in % predicted FVC< 10% per year) as previ-
ously reported [14] (for details, see Clinical analysis in S1 File).
The study was performed according to the Declaration of Helsinki and was approved by the
Ethics Committee for Clinical Experimentation of Padova. Written consent was obtained from
all subjects. None of the transplant donors were from a vulnerable population and all donors
or next of kin provided written informed consent that was freely given.
Pathological analysis
Forty one of the 73 patients underwent lung transplantation. The native lungs were fixed in for-
malin by airway perfusion and samples from upper and lower lobes were obtained and embed-
ded in paraffin. Sections 5 μm-thick were cut and stained for histological and
immunohistochemical analysis.
In all transplanted cases the diagnosis of IPF was confirmed by our expert pathologist by the
presence of an usual interstitial pneumonia (UIP) pattern [10, 11]. Fibroblastic foci and lym-
phoid follicles were counted in sections stained with hematoxylin–eosin and antiCD20 respec-
tively and expressed as number per square cm of area examined. Diffuse alveolar damage
(DAD), defined as stratified hyaline membranes, was assessed on sections stained with haema-
toxylin-eosin and considered as “present” when detected in at least 30% of each lung section.
Results were expressed as % of patients with presence of DAD over total number of patients.
Cellular inflammatory infiltrate comprising total leukocytes (CD45+), neutrophils, macro-
phages (CD68+), CD4+ and CD8+ T lymphocytes as well as B lymphocytes (CD20+) was identi-
fied by immunohistochemistry as previously described [25–26]. Each inflammatory cell type
was quantified in 20 non overlapping high power fields per slide and expressed as cells/mm2 of
area examined. Morphometric analysis was performed by an experienced researcher (GT) and
the intraobserver and interobserver reproducibility were than assessed (for details, see Patho-
logical analysis in S1 File). A representative figure of each inflammatory cell type is reported in
Figures A-E in S1 File.
Statistical analysis
Differences between groups were analyzed using Mann-Whitney U test and Fisher Exact test,
as appropriate. The relationship between different outcomes was evaluated using Spearman’s
rank correlation. Multivariate regression analysis was performed to investigate if any of the
clinical data available at diagnosis was associated with the rapid or slow rate of decline.
Results
Clinical analysis
Forty-eight of the 73 cases (66%) had a slow FVC decline while 25 (34%) had a rapid decline.
Their time course decline during the follow-up period is shown in Fig 1. Demographics and
clinical characteristics of slow and rapid progressors are summarized in Table 1.
Age, sex and smoking habits were similar in the two groups. The duration of symptoms
before diagnosis was significantly shorter in rapid as compared to slow progressors. At diagno-
sis, functional characteristics, including diffusing capacity of the lung for carbon monoxide
(DLco) and FEV1, were similar in the two groups. However, against expectations, the percent
predicted FVC at diagnosis was significantly lower in slow than in rapid progressors. By con-
trast, and as expected, at the end of follow-up the percent-predicted FVC was significantly
lower in rapid compared to slow progressors (Table 1). Six minute walking test distance and
pulmonary arterial pressure as assessed by either transthoracic echocardiography or right heart
Immune Inflammation and Disease Progression in IPF
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catheterization at the time of consideration for transplantation, were similar in slow and rapid
progressors (Table 1). As expected by the group definition, the annual decline in percent pre-
dicted FVC was lower in slow than in rapid progressors. This difference in functional decline
was even more pronounced when the FVC fall was expressed in absolute terms as ml/year (98
ml/year vs 480 ml/year in slow and rapid progressors respectively) (Table 1).
Fig 1. Rate of FVC% predicted decline over time. Time course of the % predicted FVC change in slow and
rapid decliners obtained using all the FVCmeasurements performed during follow-up for each patient.
Trends have been estimated using a linear model allowing for non-linearity of time trends, estimated via
cubic-splines. The longitudinal trends of the slow and rapid declines are significantly different (p <0.001). The
% predicted FVC at diagnosis (time 0) is significantly higher in rapid than in slow decliners (see Table 1).
doi:10.1371/journal.pone.0154516.g001
Table 1. Clinical characteristics of slow and rapid progressors.
Slow (n = 48,
66%)
Rapid (n = 25,
34%)
p value
Age at diagnosis–years 54(36–64) 54(33–69)
Male sex–n. % 37(77%) 20(80%)
Smokers–n. % 35(73%) 18(72%)
Smoking history (only smokers)–pack-years 25(0.1–120) 24(3–93)
Duration of symptom before diagnosis–months 31(2–96) 6(1–58) 0.0031
FVC at diagnosis–% predicted 61(20–94) 70(46–108) 0.022
FEV1 at diagnosis—%predicted 64(26–97) 69(45–118)
FEV1/FVC at diagnosis—% 84(71–111) 80(73–89)
DLco at diagnosis–% predicted 40 (3–100) 38(10–85)
FVC at end follow up–% predicted 52(21–87) 38(22–91) 0.0025
Follow up (from diagnosis to end study*)–
months
36(7–158) 24(12–60) 0.015
6MW distance–mt 270(40–437) 230(48–390)
mPAP–mmHg 20(10–51) 20(13–45)
FVC decline/year -% predicted 2.8(0.0–9.1) 14.2(10.2–28.0) <0.0001
FVC decline/year—ml 98(0–416) 480(297–1499) <0.0001
AE–n % 11(23%) 3(12%)
Values are expressed as numbers and (%) or medians and (ranges)
* transplant (n = 41), death (n = 14) or end follow-up (n = 18)
doi:10.1371/journal.pone.0154516.t001
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Multivariable analysis showed that a lower FVC at diagnosis (OR: 0.22, 95% CI: 0.06–0.71,
p = 0.012) and a long duration of symptoms before diagnosis (OR: 6.56, 95% CI: 1.66–25.59
p = 0.023) were the only clinical variables associated with a slow FVC decline during the follow
up. The combination of these two variables had an additive predictive effect.
During the follow up, 14 of the 73 patients (19%) developed an acute exacerbation (AE)
defined according to the diagnostic criteria proposed by Collard et al [24] (see Clinical analysis
in S1 File). Notably, most of the AE (11 of 14) occurred in the slow progression group.
Patients were treated with different regimens based on prednisone with or without azathio-
prine according to existing guidelines. There were no differences in treatment regimens
between slow and rapid progressors.
Pathological analysis
Lung pathology was examined in those patients who underwent lung transplantation (n = 41):
27 slow progressors and 14 rapid progressors. The clinical characteristics of these 41 trans-
planted patients (Table B in S1 File) were comparable to the 73 patients in the whole group.
Morphometric analysis of the explanted lung showed a prominent cellular inflammatory infil-
trate with the number of total leukocytes/mm2 (CD45+) being significantly higher in rapid
than in slow progressors (p = 0.01) (Fig 2). Both innate (neutrophils and macrophages) and
adaptive (CD4+, CD8+ and B lymphocytes) inflammatory cell numbers were significantly
higher in the rapid progressor group compared to the slow one (Fig 3).
Eleven of the 14 patients who develop AE during the follow-up period underwent lung
transplantation (8 slow and 3 rapid progressors). In view of the relevant number of subjects
who developed an AE and in order to better understand their underlying pathology, we ana-
lyzed separately the subjects who developed and those who did not develop AE in both slow
and rapid progressors (the clinical characteristics of the 4 groups are reported in the Table C in
S1 File). The slow progressors who developed AE showed a more marked overall inflammation
(CD45+) than the slow progressors who did not develop AE (Fig 4A). No difference was
observed in the rapid progressors where a severe inflammation was present in both those with
AE and those without AE. Indeed, the degree of inflammation in the rapid progressors who did
Fig 2. Total inflammatory cells in slow and rapid progressors. Number of total leukocytes (CD45+/mm2)
in the lungs of slow and rapid progressors. Horizontal bars represent median values; bottom and top of each
box plot 25th and 75th, brackets 10th and 90th percentiles. Slow: white; rapid: red.
doi:10.1371/journal.pone.0154516.g002
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not exacerbate was similar to that in the acute exacerbators, irrespective of whether they were
originally slow or rapid progressors (Fig 4A and 4B). The immune inflammatory infiltrate
comprised both innate (neutrophils) and adaptive (CD4+, CD8+ and B lymphocytes) cells, all
of which were found in significantly higher numbers in rapid progressors and acute exacerba-
tors than in slow progressors without AE (Fig 5). Of interest diffuse alveolar damage (DAD),
that is considered a characteristic feature of AE, was also found to the same extent in rapid pro-
gressors who did not exacerbate. No difference was found in the numbers of fibroblastic foci
and lymphoid follicles among the four groups of subjects (Table 2), however the number of
lymphoid follicles in IPF lungs overall was very high, more than what is usually seen in COPD
[27] where lymphoid follicles are a prominent feature. Of interest, in our study population,
emphysema was neither seen radiologically nor pathologically.
No differences were found in the clinical features, including the rate of progression and
number or type of inflammatory cells, between smokers and non-smokers in any of the groups
examined (Tables D-F in S1 File).
In slow and rapid progressors who did not develop AE the number of total leukocytes
(CD45+) was positively correlated to the yearly decline in FVC (r = 0.52, p = 0.005) and showed
a negative trend with the duration of symptoms before diagnosis (r = -0.35, p = 0.05).
Fig 3. Differential Inflammatory cells in slow and rapid progressors. Number of innate inflammatory cells
(neutrophils and macrophages) and adaptive inflammatory cells (CD4+, CD8+, and B lymphocyte) in the
lungs of slow and rapid progressors. Horizontal bars represent median values, bottom and top of each
box plot 25th and 75th, brackets 10th and 90th percentiles. Slow: white; rapid: red.
doi:10.1371/journal.pone.0154516.g003
Fig 4. Total inflammatory cells in slow and rapid progressors with and without acute exacerbation
(AE). A. Numbers of total leukocytes (CD45+/mm2) in the lungs of slow and rapid progressors; subjects who
developed and those who did not develop AE in each group are considered separately. Horizontal bars
represent median values, bottom and top of each box plot 25th and 75th, brackets 10th and 90th percentiles.
Slow not AE: white; rapid not AE: red; AE: blue. B. Microphotographs showing total leukocyte (CD45+)
infiltration (in red) in the lung of a slow decliner, a rapid decliner and an AE patient. Original magnification
X10; immunostaining with anti-CD45.
doi:10.1371/journal.pone.0154516.g004
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Discussion
In the present study we describe the clinical course of a group of patients with IPF referred to
our center for lung transplantation and characterize their pathological features. We found that
two clinical phenotypes can be clearly identified (slow and a rapid progressors) and that sub-
stantial differences in their pathological features are present, with the degree of inflammation,
involving innate and adaptive immunity, being the most striking one. Conceivably these differ-
ences in lung pathology might be important contributors to the different clinical behaviour.
Using the criteria proposed by Boon and colleagues [14], based on the fall in percent pre-
dicted FVC/year, we differentiated our patients into slow (66%) and rapid (34%) progressors.
On average, the absolute yearly fall in FVC was 98 ml/year in the “slow” decliners and 480 ml/
year in the “rapid” ones. The median fall for the whole population was 215 ml/year, a value
similar to that recently reported in large clinical trials [28, 29], which suggests that our popula-
tion is well representative of the IPF population in general. In view of the clinical importance
of the different progression, we investigated whether the rate of decline could be predicted at
diagnosis based on any of the clinical and/or functional variables available at presentation. We
found that a low value of FVC at diagnosis and a long duration of symptoms before diagnosis,
as previously described by Selman and colleagues [13], were the best fitting predictors for the
likelihood of having a slow, instead of a rapid, FVC decline. The possibility of distinguishing
between slow and rapid progressors early in the disease course is clinically relevant, especially
in view of the current availability of medical therapies that are effective in slowing functional
decline and disease progression in the early stage of the disease [28–31].
Fig 5. Differential inflammatory cells in slow and rapid progressors with and without acute
exacerbation (AE). Number of innate inflammatory cells (neutrophils, macrophages) and adaptive
inflammatory cells (CD4+, CD8+, and B lymphocytes) in the lungs of slow and rapid progressors; subjects
who developed and those who did not develop AE are considered separately. Horizontal bars represent
median values, bottom and top of each box plot 25th and 75th, brackets 10th and 90th percentiles. Slow not
AE: white; rapid not AE: red; AE: blue. * P<0.001 compared to slow who develop AE and rapid who do not
develop AE
doi:10.1371/journal.pone.0154516.g005
Table 2. Pathological characteristics of slow and rapid progressors with and without AE.
Slow (n = 27) Rapid (n = 14)
Not AE (n = 19) AE (n = 8) Not AE (n = 11) AE (n = 3)
DAD 4 (21%)* 6 (75%) 10 (91%) 3 (100%)
Fibroblastic Foci—n/cm2 4.7 (0.4–11.7) 2.2 (1.9–4.1) 3 (1–7.3) 4 (1.1–6.1)
Lymphoid follicles—n/cm2 5(1–16) 9(2–16) 6(2–11) 9(9–11)
DAD is expressed as number (%) of subjects with presence of DAD in their lung sections.
Fibroblastic foci and lymphoid follicles are expressed as medians and (ranges).
* p<0.05 compared to AE
doi:10.1371/journal.pone.0154516.t002
Immune Inflammation and Disease Progression in IPF
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It is of interest that, at presentation, rapid progressors had a higher % predicted FVC than
the slow progressors, a finding somehow unexpected. A possible explanation is that a more
rapid change in FVC in the rapid decliners is perceived more readily, thus promoting a faster
seek for medical attention. This finding is important since it may suggest that the value of the
FVC at diagnosis by itself does not reflect the pre-diagnosis rapidity of decline nor can predict
the future rate of progression [32], unless the duration of symptoms before diagnosis is also
taken in consideration, as our data suggest.
Acute exacerbation (AE), an acute worsening of the underlying disease without obvious
cause [24], is a clinically relevant and often fatal event in IPF. The incidence of AE estimated
from clinical trials with short follow-up is between 5 and 10% [1, 24]. However, 19% of our
patients developed AE during follow-up and the majority of them, 11 out of 14, belonged to
the slow declining group, in line with previous reports [13]. The high rate of AE in our study
might be due to the long follow up period or, more likely, to the fact that being a transplant
centre, we followed a selected population. The high incidence of AE seen in our population is
in line with a recently reported incidence of 20.7% in a 3-years follow up study in IPF [33].
Once we had defined the different clinical course in our population, we hypothesized that
different progression might be associated with distinct underlying pathological findings.
Indeed, important differences in lung pathology were observed between slow and rapid pro-
gressors, consisting mainly on the presence of an extensive degree of innate and adaptive
immune inflammation in the rapid group, more prominent than in the slow progressors. Of
interest, we did not observe differences in lung pathology between subjects who experienced an
AE and rapid progressors who did not exacerbate, including the presence of DAD, an abnor-
mality considered a characteristic feature of AE. This observation would support the hypothe-
sis that rapid progression might be the consequence of repeated, but silent, acute events. The
relation between the occurrence of AE and the type of clinical progression is of interest. We
have found in our population that the majority of AE occurred among the slow progressors,
and that the main difference between patients with an AE and slow progressors who did not
develop an exacerbation, is the extent of lung immune inflammation. Therefore, it could be
speculated that an idiopathic or induced “acceleration” of the generally “contained” immune
inflammatory reaction present in slow progressors could account for the exuberant clinical and
pathological picture seen in AE.
The results of the detailed quantitative pathological analysis in IPF lungs appear to support
a contribution of inflammation in determining disease behaviour in IPF. Despite the increased
evidences that immunology might play a role in IPF [15–23, 34–40], inflammation is not con-
sidered an important component of UIP or a factor contributing to the progression or patho-
genesis of the disease. Furthermore, previous pathological descriptions, performed in lung
biopsies from IPF patients at the time of diagnosis, reported no differences in pathology
between the slow and rapid decliners [13]. Unfortunately, we could not examine the lung
pathology at the time of diagnosis in our patients, so we do not know if some differences were
already present at that stage.
The presence of an exuberant immune inflammatory infiltrate, found predominantly in the
rapid progressors, is consistent with the gene expression profile reported by Boon and col-
leagues [14], who indeed described the activation of important pro-inflammatory pathways
that may potentially play a role in the immune activation and disease progression of the rapid
decliners [14]. Our findings are also in keeping with previous observations showing that lym-
phocyte density in IPF lung is associated with FVC decline [21] and poor survival [34]. More-
over, in keeping with an important role of immune activation and inflammation, recent
publications suggest that increased expression of pro-inflammatory factors may predispose to
worse outcomes in IPF [15–23, 35–38]. For instance, CXCL13, a chemokine involved in B cell
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trafficking and recruitment, has been shown to be related with disease severity and survival
[20, 37]. In line with these reports is also the presence of B cell aggregates [20, 39, 40] and
highly differentiated circulating B cells in patients with IPF [39], findings usually observed in
autoimmune syndromes. In this context, it is of interest to note that autoantibodies to heat
shock protein 70 [15] and periplakin [23], which have been identified in serum and bronchoal-
veolar lavage of patients with IPF, have been reported to be associated with a more severe dis-
ease, further supporting the presence of an autoimmune response in the pathogenesis of IPF.
In this regard our finding of an increased number of B lymphocytes in the lungs of rapid pro-
gressors supports a potential role for these cells, along with T lymphocytes, in the development
of an adaptive immune response, possibly contributing to the course of the disease.
Of interest the two drugs recently reported to be effective in the treatment of IPF, Ninteda-
nib and Pirfenidone [28, 29], beside their antifibrotic effect are known to have even antinflam-
matory properties, hence some of their action could be mediated by a control of the immune
inflammation present in IPF lungs.
We are well aware that by studying the pathology of the explanted lung we are looking at
the “terminal”, or at least advanced, stages of the disease. In other words, we may be looking at
the consequence rather than the cause of the pathologic process. Yet, the clear differences in
pathology found between slow and rapid progressors, both at a terminal stage of their disease,
validate the significance of our findings and indicate that the “end stage” itself cannot explain
the enhanced immune inflammatory process observed in rapid progressors.
Likely our findings in explanted lungs showing the possible role of inflammation in the dif-
ferent patterns of progression, slow and rapid, may help to understand better the disease. Fur-
thermore, this knowledge might allow the search of other ways of assessing inflammatory and
immune mechanisms, without biopsies, either by blood and bronchoalveolar lavage (BAL)
analysis or by radiology.
In conclusion, in a cohort of IPF patients referred for lung transplantation, an innate and
adaptive inflammatory process of the lung is a significant feature and appears to be an impor-
tant determinant of the rate of disease progression. These findings may provide a basis for
future investigation on predicting outcomes and personalized treatment in this heterogeneous
disease.
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